Center Laboratories, Inc. (TPEX:4123)

Market Cap	30.57B
Revenue (ttm)	1.57B
Net Income (ttm)	1.78B
Shares Out	746.53M
EPS (ttm)	2.28
PE Ratio	17.99
Forward PE	n/a
Dividend	0.71 (1.75%)
Ex-Dividend Date	Oct 3, 2025

Volume	1,001,812
Average Volume	2,438,239
Open	40.95
Previous Close	40.95
Day's Range	40.20 - 41.00
52-Week Range	29.12 - 42.40
Beta	0.33
RSI	64.55
Earnings Date	Mar 16, 2026

About Center Laboratories

Center Laboratories, Inc., a pharmaceutical company, develops, manufactures, and sells pharmaceuticals in Taiwan and internationally. The company offers general medication pharmaceuticals comprising antipyretics and analgesics, bronchodilators, anti-inflammatory preparations, antihistamines, expectorants, narcotic antitussives and expectorants, gastrointestinal preparations, non-narcotic antitussives and expectorants, and other medicines. It also offers central nervous system medication consisting of treatments for cerebrovascular disease, deme...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4123

Financial Performance

In 2024, Center Laboratories's revenue was 1.62 billion, an increase of 16.06% compared to the previous year's 1.39 billion. Losses were -1.10 billion, 10.9% more than in 2023.